Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 21, Issue 9, 2003, Pages 1760-1766

  Adjei, Alex A ^a   Mauer, Ann ^a   Bruzek, Laura ^a   Marks, Randolph S ^a   Hillman, Shauna ^a   Geyer, Susan ^a   Hanson, Lorelei J ^a   Wright, John J ^a   Erlichman, Charles ^a   Kaufmann, Scott H ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; FARNESYL TRANS TRANSFERASE; QUINOLONE DERIVATIVE; TRANSFERASE;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHEEK MUCOSA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MEDICAL DOCUMENTATION; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; AGED; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; MONONUCLEAR CELL; MOUTH MUCOSA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PATHOLOGY; SURVIVAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALKYL AND ARYL TRANSFERASES; ANEMIA; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOUTH MUCOSA; NEUTROPENIA; QUINOLONES; SURVIVAL;

EID: 0038362742     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.075     Document Type: Article

References (37)

1. Downward J: Ras signaling and apoptosis. Curr Opin Genet Dev 8:9-54, 1998
2. Bos JL: Ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989
3. Kato K, Cox AD, Hisaka MM, et al: Isoprenoid addition to Ras proteins is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A 89:6403-6407, 1992
4. Sepp-Lorenzino L, Ma Z, Rands E, et al: A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and independent growth of human tumor cell lines. Cancer Res 55:5302-5309, 1995
5. End DW: Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest New Drugs 17:241-258, 1999
6. Rowinsky EK, Windle JJ, Von Hoff DD: Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 17:3631-3652, 1999
7. End DW, Smets G, Todd AV, et al: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131-137, 2001
8. Crul M, de Klerk GJ, Swart M, et al: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 20:2726-2735, 2002
9. Karp JE, Lancet JE, Kaufmann SH, et al: Clinical and biologic activity of farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical trial. Blood 97:3361-3369, 2001
10. Johnston SR, Hickish T, Houston S, et al: Efficacy and tolerability of two dosing regimens of R115777, a farnesyl protein transferase inhibitor, in patients with advanced breast cancer. Proc Am Soc Clin Oncol 21:138a, 2002 (abstr 138)
11. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
12. Adjei AA, Erlichman C, Davis JN, et al: A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity. Cancer Res 60:1871-1877, 2000
13. Adjei AA, Davis JN, Erlichman C, et al: Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 6:2318-2325, 2000
14. Kaufmann SH, Svingen PA, Gore SD, et al: Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood 89:2098-2104, 1997
15. Smith PK, Krohn RI, Hermanson GT, et al: Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85, 1985
16. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
17. Kaplan E, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Duffy D, Santner T: Confidence intervals for a binomial parameter based on multistage tests. Biometrics 43:81-93, 1987
19. Inglese J, Glickman JF, Lorenz W, et al: Isoprenylation of a protein kinase: Requirement of farnesylation/alpha-carboxyl methylation for full enzymatic activity of rhodopsin kinase. J Biol Chem 267:1422-1425, 1992
20. Lai RK, Perez-Sala D, Canada FJ, et al: The gamma subunit of transducin is farnesylated. Proc Natl Acad Sci U S A 87:7673-7677, 1990
21. Adjei AA: Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst 93:1062-1074, 2001
22. Zujewski J, Horak ID, Bol CJ, et al: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 I advanced cancer. J Clin Oncol 18:927-941, 2000
23. Hudes G, Schol J, Baab J, et al: Phase I clinical and pharmacokinetic trial of the farnesyl transferase inhibitor R115777 on a 21-day dosing schedule. Proc Am Soc Clin Oncol 18:156a, 1999 (abstr 601)
24. Reuter CW, Morgan MA, Bergman L: Targeting Ras signaling pathway: A rational, mechanism-based treatment for hematologic malignancies. Blood 96:1655-1669, 2000
25. Adjei AA: Farnesyltransferase inhibitors, in Schlisky R, Giaccone G, Sondel P (eds): Cancer Chemotherapy and Biologic Response Modifiers: Annual 19. New York, NY, Elsevier Science, 2001, pp 149-164
26. Zhang FL, Kirschmeier P, Carr D, et al: Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 272:10232-10239, 1997
27. Karp JE, Kaufmann SH, Adjei AA, et al: Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol 13:470-476, 2001
28. Lebowitz PF, Prendergast GC: Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho. Oncogene 17:1439-1445, 1998
29. Jiang K, Coppola D, Crespo NC, et al: The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 20:139-148, 2000
30. Ashar HR, James L, Gray K, et al: FTIs block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275:30451-30457, 2000
31. Adjei AA, Bruzek LM, Erlichman C, et al: Combination studies with the farnesyltransferase inhibitor R115777 and chemotherapy agents. Eur J Cancer 37:792, 2001 (suppl 6)
32. Shi B, Yaremko B, Hajian G, et al: The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 46:387-393, 2000
33. Moasser MM, Sepp-Lorenzino L, Kohl NE, et al: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci U S A 95:1369-1374, 1998
34. Sun J, Blaskovich MA, Knowles D, et al: Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 59:4919-4926, 1999
35. Brognard J, Clark AS, Ni Y, et al: Akt/Protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986-3997, 2001
36. Zinda MJ, Johnson MA, Paul JD, et al: AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin Cancer Res 7:2475-2479, 2001
37. Massion PP, Kuo W-L, Stokoe D, et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 62:3636-3640, 2002